Overview

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy volunteers compared to placebo; and to investigate the general safety, tolerability and pharmacokinetic profile of CX157 tablets at steady state compared to placebo.
Phase:
Phase 1
Details
Lead Sponsor:
CeNeRx BioPharma Inc.
Treatments:
Tyramine